Biopharma

Monoclonal antibodies require careful formulation due to their inherent stability limitations. Polysorbates are commonly used to stabilize mAbs, but they...

Abstract Nanobody molecules, derived from heavy-chain only antibodies in camelids, represent the next generation of biotherapeutics. In addition to low...

A library of 16 lipid nanoparticle (LNP) formulations with orthogonally varying lipid molar ratios was designed and synthesized, using polyadenylic acid ...

Atorvastatin (ATV) is a first-line drug for the treatment of hyperlipidemia. This drug presents biopharmaceutical problems, partly due to its...

Abstract Three-dimensional (3D) printing is a promising approach for the stabilization and delivery of non-living biologics. This versatile tool builds...

Monoclonal antibodies (mAbs) hold promise for treating Parkinson's disease (PD), but their therapeutic use is hindered by poor delivery to...

TREHALOSE SG JP, USP-NF, Ph. Eur., CP High-purity and low endotoxin injectable grade trehalose TREHALOSE SG is an injectable grade...

A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010...

Formulation of lipid-based drug delivery systems is recognized as a promising strategy to increase bioavailability of simvastatin (SV). The purpose...

By: Ben Nelson, PhD, and Chris Wilcox   Trehalose is a non-reducing disaccharide consisting of two glucose molecules linked by...